Business
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
CHICAGO, May 08, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":808,"height":274,"url":"https://media.zenfs.com/en/business-wire.com/117d8659c378e75cc3fa5b938de29bef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GfbwuEekFVK9eADBecQH5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/117d8659c378e75cc3fa5b938de29bef","width":808,"height":274},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/obXgdNiML9lsZ3eOxF6Pzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MTY7aD01NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/117d8659c378e75cc3fa5b938de29bef","width":808,"height":274}},"lazy":false},{"type":"text","content":"Total revenue increased 48% YoY to over $60 million","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"Recorlev® revenue grew 141% on YoY basis","length":40,"tagName":"p","attribs":{}},{"type":"text","content":"Tightens full-year total revenue 2025 guidance to $260 million to $275 million","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"Announces upcoming Investor and Analyst Day on June 3rd in New York City","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"Hosts conference call and webcast today at 8:30 a.m. ET","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"CHICAGO, May 08, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance.","length":377,"tagName":"p"},{"type":"text","content":""We’re very pleased with our strong start to the year, delivering another quarter of outstanding revenue growth," said John Shannon, Xeris’ Chief Executive Officer. "Our performance reflects sustained momentum across the portfolio, led by strong demand for Recorlev and is a testament to the disciplined execution of our growth strategy." Mr. Shannon continued, "Given our exceptional first quarter performance, as well as strong continued momentum and confidence in the business, we have tightened full-year 2025 total revenue guidan...